Cargando…
The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients
Recurrent disease and treatment-associated chemoresistance are the two main factors accounting for poor clinical outcomes of ovarian cancer (OC) patients. Both can be associated with cancer stem cells (CSCs), which contribute to cancer formation, progression, chemoresistance, and recurrence. Hence,...
Autores principales: | Izycka, Natalia, Rucinski, Marcin, Andrzejewska, Malgorzata, Szubert, Sebastian, Nowak-Markwitz, Ewa, Sterzynska, Karolina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916537/ https://www.ncbi.nlm.nih.gov/pubmed/36768723 http://dx.doi.org/10.3390/ijms24032400 |
Ejemplares similares
-
Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development
por: Sterzyńska, Karolina, et al.
Publicado: (2018) -
PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations
por: Świerczewska, Monika, et al.
Publicado: (2019) -
ALDH1A3 in CSCs
por: Sullivan, Kelly E., et al.
Publicado: (2017) -
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
por: Lugli, A, et al.
Publicado: (2010) -
The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis
por: Chen, Engeng, et al.
Publicado: (2016)